Background

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein. It has become one of the most-discussed “recovery peptides” in fitness communities. Until now, no comprehensive review of the actual literature existed.

What the review found

The authors screened 1,142 records and included 38 studies:

  • 33 animal studies, mostly rat tendon-transection models, consistently showed faster collagen organization and improved load-to-failure in treated groups.
  • 5 human case reports — none were controlled trials.
  • Zero randomized human trials met inclusion criteria.
  • Safety data in animals out to 30 days appears clean; long-term human safety is unknown.

How it was done

Standard PRISMA-style systematic review across PubMed, Embase, and Cochrane databases through March 2026. Two reviewers screened titles and abstracts independently; disagreements resolved by a third.

What it means in practice

If you’re reading peptide forums, you’ve seen claims that BPC-157 “heals tendons.” The animal evidence is genuinely promising. The human evidence is almost entirely anecdotal. Anyone using BPC-157 today is in an n=1 experiment — there are no Phase II or III trials to point to.

Editorial note: BPC-157 is not approved by the FDA for any indication. This summary is not medical advice.